Cangrelor News
Cangrelor currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Cangrelor with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous...
- Evidence level: L5
- Predicted indications (20):
- hemoglobinopathy (98.4%)
- myocardial infarction (98.0%)
- partial deletion of the short arm of chromosome 16 (97.8%)
- beta-thalassemia with other manifestations (97.8%)
- hemolytic anemia due to glucophosphate isomerase deficiency (97.6%)
- pyruvate kinase deficiency of red cells (97.5%)
- pyropoikilocytosis, hereditary (97.4%)
- posteroinferior myocardial infarction (97.4%)
- posterolateral myocardial infarction (97.4%)
- septal myocardial infarction (97.3%)
- rheumatoid arthritis (97.3%)
- coronary thrombosis (97.2%)
- myocardial infarction (disease) (96.8%)
- coronary stenosis (96.7%)
- thrombotic disease (96.4%)
- gout (96.1%)
- congenital coronary artery anomaly (96.0%)
- colobomatous microphthalmia-rhizomelic dysplasia syndrome (95.6%)
- postoperative ventricular dysfunction (95.2%)
- brachydactyly-syndactyly syndrome (95.0%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.